Aprepitant (Emend) for Prevention of Nausea and Vomiting Due to Cancer Chemotherapy
Aprepitant (Emend - Merck), the first substance P/neurokinin 1 (NK1) receptor antagonist to be approved by the FDA, is now available for oral use with corticosteroids and selective serotonin (5-HT3) receptor antagonists to prevent nausea and vomiting caused by highly emetogenic anticancer drugs such as cisplatin....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Aprepitant (Emend) for Prevention of Nausea and Vomiting Due to Cancer Chemotherapy
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1162
Article Code: 1162b
Date: August 4, 2003
Volume: 45
Pages: 62-63
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1162
Article Code: 1162b
Date: August 4, 2003
Volume: 45
Pages: 62-63
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)